MNMD vs. TLRY, CRON, USNA, CGC, BTMD, ACB, CDXC, MDWD, FTLF, and BGXX
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Tilray (TLRY), Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), MediWound (MDWD), FitLife Brands (FTLF), and Bright Green (BGXX). These companies are all part of the "medicinals & botanicals" industry.
Mind Medicine (MindMed) (NASDAQ:MNMD) and Tilray (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.
Mind Medicine (MindMed) has a net margin of 0.00% compared to Tilray's net margin of -43.98%. Tilray's return on equity of -2.68% beat Mind Medicine (MindMed)'s return on equity.
Tilray received 404 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 91.49% of users gave Mind Medicine (MindMed) an outperform vote while only 59.28% of users gave Tilray an outperform vote.
Mind Medicine (MindMed) currently has a consensus target price of $22.00, suggesting a potential upside of 134.17%. Tilray has a consensus target price of $2.71, suggesting a potential upside of 48.00%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher probable upside, equities analysts plainly believe Mind Medicine (MindMed) is more favorable than Tilray.
In the previous week, Tilray had 4 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 15 mentions for Tilray and 11 mentions for Mind Medicine (MindMed). Mind Medicine (MindMed)'s average media sentiment score of 0.81 beat Tilray's score of 0.43 indicating that Mind Medicine (MindMed) is being referred to more favorably in the media.
Mind Medicine (MindMed) has higher earnings, but lower revenue than Tilray. Tilray is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.
27.9% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 9.4% of Tilray shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by insiders. Comparatively, 0.7% of Tilray shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Mind Medicine (MindMed) has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500. Comparatively, Tilray has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.
Summary
Mind Medicine (MindMed) beats Tilray on 12 of the 18 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
Free MNMD Stock Alerts